Advertisement

Index by author

May 01, 1995; Volume 47,Issue 5

A

  1. Adachi, Y

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

  2. Alejo-Herberg, A

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  3. Ambrosini, A

    1. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro.
      A Ambrosini, L Bresciani, S Fracchia, N Brunello and G Racagni
      Molecular Pharmacology May 1995, 47 (5) 1057-1064;

B

  1. Bai, R

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  2. Battaglia, G

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

  3. Beere, H M

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  4. Beidler, D R

    1. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
      D R Beidler and Y C Cheng
      Molecular Pharmacology May 1995, 47 (5) 907-914;

  5. Benchokroun, Y

    1. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
      S Lelièvre, Y Benchokroun and A K Larsen
      Molecular Pharmacology May 1995, 47 (5) 898-906;

  6. Bittman, R

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

  7. Botto, J M

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  8. Bradford, B U

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

  9. Bresciani, L

    1. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro.
      A Ambrosini, L Bresciani, S Fracchia, N Brunello and G Racagni
      Molecular Pharmacology May 1995, 47 (5) 1057-1064;

  10. Brindley, D N

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

  11. Brodbeck, R M

    1. Residue 78 in the second transmembrane domain of the neurokinin-1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses.
      R M Brodbeck, B S Sachais and J E Krause
      Molecular Pharmacology May 1995, 47 (5) 1065-1071;

  12. Brunello, N

    1. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro.
      A Ambrosini, L Bresciani, S Fracchia, N Brunello and G Racagni
      Molecular Pharmacology May 1995, 47 (5) 1057-1064;

  13. Bruno, V

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

  14. Byun, H S

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

C

  1. Catapano, C V

    1. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis.
      C V Catapano, J S Dayton, B S Mitchell and D J Fernandes
      Molecular Pharmacology May 1995, 47 (5) 948-955;

  2. Chabry, J

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  3. Chen, J Q

    1. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6.
      J Q Chen, A Ström, J A Gustafsson and E T Morgan
      Molecular Pharmacology May 1995, 47 (5) 940-947;

  4. Chen, S

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  5. Cheng, Y C

    1. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
      D R Beidler and Y C Cheng
      Molecular Pharmacology May 1995, 47 (5) 907-914;

  6. Chresta, C M

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  7. Copani, A

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

D

  1. Dayton, J S

    1. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis.
      C V Catapano, J S Dayton, B S Mitchell and D J Fernandes
      Molecular Pharmacology May 1995, 47 (5) 948-955;

  2. Deng, P S

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  3. Diaz Cruz, P J

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

  4. Dive, C

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  5. Dolenga, M P

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

  6. Du, Y L

    1. Regulation of rat 5-hydroxytryptamine type 2 receptor gene activity: identification of cis elements that mediate basal and 5-hydroxytryptamine-dependent gene activation.
      Y L Du, B D Wilcox and J J Jeffrey
      Molecular Pharmacology May 1995, 47 (5) 915-922;

  7. Duffy, P A

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

E

  1. Ebenstein, D

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  2. Esbenshade, T A

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

  3. Evans, C J

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

F

  1. Fernandes, D J

    1. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis.
      C V Catapano, J S Dayton, B S Mitchell and D J Fernandes
      Molecular Pharmacology May 1995, 47 (5) 948-955;

  2. Fracchia, S

    1. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro.
      A Ambrosini, L Bresciani, S Fracchia, N Brunello and G Racagni
      Molecular Pharmacology May 1995, 47 (5) 1057-1064;

  3. Friedlos, F

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  4. Fung, M

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

G

  1. Gomez-Muñoz, A

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

  2. Gully, D

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  3. Gustafsson, J A

    1. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6.
      J Q Chen, A Ström, J A Gustafsson and E T Morgan
      Molecular Pharmacology May 1995, 47 (5) 940-947;

H

  1. Hales, T G

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

  2. Hamel, E

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  3. Hickman, J A

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  4. Hildebrandt, J D

    1. Gi is involved in ethanol inhibition of L-type calcium channels in undifferentiated but not differentiated PC-12 cells.
      D Mullikin-Kilpatrick, N D Mehta, J D Hildebrandt and S N Treistman
      Molecular Pharmacology May 1995, 47 (5) 997-1005;

  5. Hirasawa, A

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

  6. Holtzclaw, L

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

I

  1. Iimuro, Y

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

J

  1. Jeffrey, J J

    1. Regulation of rat 5-hydroxytryptamine type 2 receptor gene activity: identification of cis elements that mediate basal and 5-hydroxytryptamine-dependent gene activation.
      Y L Du, B D Wilcox and J J Jeffrey
      Molecular Pharmacology May 1995, 47 (5) 915-922;

K

  1. Kadiiska, M

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

  2. Kankaanranta, H

    1. Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes.
      H Kankaanranta and E Moilanen
      Molecular Pharmacology May 1995, 47 (5) 1006-1013;

  3. Keating, M J

    1. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
      L Y Yang, L Li, M J Keating and W Plunkett
      Molecular Pharmacology May 1995, 47 (5) 1072-1079;

  4. Kepler, J A

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  5. Kitabgi, P

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  6. Klein, D C

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

  7. Knecht, K T

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

  8. Knox, R

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  9. Krause, J E

    1. Residue 78 in the second transmembrane domain of the neurokinin-1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses.
      R M Brodbeck, B S Sachais and J E Krause
      Molecular Pharmacology May 1995, 47 (5) 1065-1071;

  10. Kuznetsov, A

    1. kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes.
      G H Ma, R J Miller, A Kuznetsov and L H Philipson
      Molecular Pharmacology May 1995, 47 (5) 1035-1040;

L

  1. Labbé-Jullié, C

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  2. Larsen, A K

    1. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
      S Lelièvre, Y Benchokroun and A K Larsen
      Molecular Pharmacology May 1995, 47 (5) 898-906;
    2. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  3. Law, P Y

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

  4. Leanza, G

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

  5. Lelièvre, S

    1. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
      S Lelièvre, Y Benchokroun and A K Larsen
      Molecular Pharmacology May 1995, 47 (5) 898-906;

  6. Lewis, A D

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  7. Li, L

    1. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
      L Y Yang, L Li, M J Keating and W Plunkett
      Molecular Pharmacology May 1995, 47 (5) 1072-1079;

  8. Loh, H H

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

M

  1. Ma, G H

    1. kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes.
      G H Ma, R J Miller, A Kuznetsov and L H Philipson
      Molecular Pharmacology May 1995, 47 (5) 1035-1040;

  2. Maffrand, J P

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  3. Martin, A

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

  4. Mas, M V

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  5. Mazella, J

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

  6. Mehta, N D

    1. Gi is involved in ethanol inhibition of L-type calcium channels in undifferentiated but not differentiated PC-12 cells.
      D Mullikin-Kilpatrick, N D Mehta, J D Hildebrandt and S N Treistman
      Molecular Pharmacology May 1995, 47 (5) 997-1005;

  7. Miller, R J

    1. kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes.
      G H Ma, R J Miller, A Kuznetsov and L H Philipson
      Molecular Pharmacology May 1995, 47 (5) 1035-1040;

  8. Minneman, K P

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

  9. Mitchell, B S

    1. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis.
      C V Catapano, J S Dayton, B S Mitchell and D J Fernandes
      Molecular Pharmacology May 1995, 47 (5) 948-955;

  10. Moilanen, E

    1. Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes.
      H Kankaanranta and E Moilanen
      Molecular Pharmacology May 1995, 47 (5) 1006-1013;

  11. Moldéus, P

    1. Metabolism and cytotoxicity of propyl gallate in isolated rat hepatocytes: effects of a thiol reductant and an esterase inhibitor.
      Y Nakagawa, K Nakajima, S Tayama and P Moldéus
      Molecular Pharmacology May 1995, 47 (5) 1021-1027;

  12. Morgan, E T

    1. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6.
      J Q Chen, A Ström, J A Gustafsson and E T Morgan
      Molecular Pharmacology May 1995, 47 (5) 940-947;

  13. Mullikin-Kilpatrick, D

    1. Gi is involved in ethanol inhibition of L-type calcium channels in undifferentiated but not differentiated PC-12 cells.
      D Mullikin-Kilpatrick, N D Mehta, J D Hildebrandt and S N Treistman
      Molecular Pharmacology May 1995, 47 (5) 997-1005;

  14. Murphy, T J

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

N

  1. Nakagawa, Y

    1. Metabolism and cytotoxicity of propyl gallate in isolated rat hepatocytes: effects of a thiol reductant and an esterase inhibitor.
      Y Nakagawa, K Nakajima, S Tayama and P Moldéus
      Molecular Pharmacology May 1995, 47 (5) 1021-1027;

  2. Nakajima, K

    1. Metabolism and cytotoxicity of propyl gallate in isolated rat hepatocytes: effects of a thiol reductant and an esterase inhibitor.
      Y Nakagawa, K Nakajima, S Tayama and P Moldéus
      Molecular Pharmacology May 1995, 47 (5) 1021-1027;

  3. Nicoletti, F

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

O

  1. O'Brien, L

    1. Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides.
      A Gomez-Muñoz, P A Duffy, A Martin, L O'Brien, H S Byun, R Bittman and D N Brindley
      Molecular Pharmacology May 1995, 47 (5) 833-839;

P

  1. Pecht, I

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  2. Pellitteri, R

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

  3. Pettit, G R

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  4. Philipson, L H

    1. kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes.
      G H Ma, R J Miller, A Kuznetsov and L H Philipson
      Molecular Pharmacology May 1995, 47 (5) 1035-1040;

  5. Piros, E T

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

  6. Plunkett, W

    1. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
      L Y Yang, L Li, M J Keating and W Plunkett
      Molecular Pharmacology May 1995, 47 (5) 1072-1079;

  7. Prather, P L

    1. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
      E T Piros, P L Prather, H H Loh, P Y Law, C J Evans and T G Hales
      Molecular Pharmacology May 1995, 47 (5) 1041-1049;

R

  1. Racagni, G

    1. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro.
      A Ambrosini, L Bresciani, S Fracchia, N Brunello and G Racagni
      Molecular Pharmacology May 1995, 47 (5) 1057-1064;

  2. Reinsprecht, M

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  3. Rodriguez, I R

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

  4. Rohn, M H

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  5. Romanin, C

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  6. Russell, J T

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

  7. Russo, A

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

S

  1. Sachais, B S

    1. Residue 78 in the second transmembrane domain of the neurokinin-1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses.
      R M Brodbeck, B S Sachais and J E Krause
      Molecular Pharmacology May 1995, 47 (5) 1065-1071;

  2. Schaad, N C

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

  3. Schindler, H

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  4. Schmidt, J M

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  5. Skladanowski, A

    1. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.
      H M Beere, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen and J A Hickman
      Molecular Pharmacology May 1995, 47 (5) 986-996;

  6. Smith, H E

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

  7. Spadinger, R J

    1. Blockade of capacitive Ca2+ influx by Cl- channel blockers inhibits secretion from rat mucosal-type mast cells.
      M Reinsprecht, M H Rohn, R J Spadinger, I Pecht, H Schindler and C Romanin
      Molecular Pharmacology May 1995, 47 (5) 1014-1020;

  8. Stanzani, S

    1. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.
      A Copani, V Bruno, G Battaglia, G Leanza, R Pellitteri, A Russo, S Stanzani and F Nicoletti
      Molecular Pharmacology May 1995, 47 (5) 890-897;

  9. Strader, C D

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

  10. Ström, A

    1. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6.
      J Q Chen, A Ström, J A Gustafsson and E T Morgan
      Molecular Pharmacology May 1995, 47 (5) 940-947;

  11. Summerfield, A E

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

T

  1. Tanaka, T

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

  2. Tayama, S

    1. Metabolism and cytotoxicity of propyl gallate in isolated rat hepatocytes: effects of a thiol reductant and an esterase inhibitor.
      Y Nakagawa, K Nakajima, S Tayama and P Moldéus
      Molecular Pharmacology May 1995, 47 (5) 1021-1027;

  3. Taylor, G F

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  4. Thurman, R G

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

  5. Toney, J H

    1. Tissue-specific pharmacology of testosterone and 5 alpha-dihydrotestosterone analogues: characterization of a novel canine liver androgen-binding protein.
      A E Summerfield, P J Diaz Cruz, M P Dolenga, H E Smith, C D Strader and J H Toney
      Molecular Pharmacology May 1995, 47 (5) 1080-1088;

  6. Treistman, S N

    1. Gi is involved in ethanol inhibition of L-type calcium channels in undifferentiated but not differentiated PC-12 cells.
      D Mullikin-Kilpatrick, N D Mehta, J D Hildebrandt and S N Treistman
      Molecular Pharmacology May 1995, 47 (5) 997-1005;

  7. Tsai, T M

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  8. Tsujimoto, G

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;

V

  1. Vanecek, J

    1. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism.
      N C Schaad, J Vanecek, I R Rodriguez, D C Klein, L Holtzclaw and J T Russell
      Molecular Pharmacology May 1995, 47 (5) 923-933;

  2. Vaughan, R A

    1. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping.
      R A Vaughan
      Molecular Pharmacology May 1995, 47 (5) 956-964;

  3. Vincent, J P

    1. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
      C Labbé-Jullié, J M Botto, M V Mas, J Chabry, J Mazella, J P Vincent, D Gully, J P Maffrand and P Kitabgi
      Molecular Pharmacology May 1995, 47 (5) 1050-1056;

W

  1. Wilcox, B D

    1. Regulation of rat 5-hydroxytryptamine type 2 receptor gene activity: identification of cis elements that mediate basal and 5-hydroxytryptamine-dependent gene activation.
      Y L Du, B D Wilcox and J J Jeffrey
      Molecular Pharmacology May 1995, 47 (5) 915-922;

  2. Williams, M D

    1. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
      R Bai, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit and E Hamel
      Molecular Pharmacology May 1995, 47 (5) 965-976;

  3. Workman, P

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

  4. Wu, K

    1. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
      S Chen, R Knox, A D Lewis, F Friedlos, P Workman, P S Deng, M Fung, D Ebenstein, K Wu and T M Tsai
      Molecular Pharmacology May 1995, 47 (5) 934-939;

X

  1. Xuang, Q H

    1. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells.
      K T Knecht, Y Adachi, B U Bradford, Y Iimuro, M Kadiiska, Q H Xuang and R G Thurman
      Molecular Pharmacology May 1995, 47 (5) 1028-1034;

Y

  1. Yang, L Y

    1. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
      L Y Yang, L Li, M J Keating and W Plunkett
      Molecular Pharmacology May 1995, 47 (5) 1072-1079;

  2. Yano, J

    1. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.
      T A Esbenshade, A Hirasawa, G Tsujimoto, T Tanaka, J Yano, K P Minneman and T J Murphy
      Molecular Pharmacology May 1995, 47 (5) 977-985;
Back to top

In this issue

Advertisement